Pure Global
NCT06061211

Treadmill With TENS on Functional Capacity &Muscle Oxygenation in PAD Patients

Treadmill Training With TENS Impact on Walking Distance, Pain and Peak Velocity in Patients With Peripheral Arterial Disease
Cairo University·ClinicalTrials.gov·otherNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Peripheral Arterial Disease
Drug/Device/Intervention
TREADMILL(PRECOR 964i treadmill) with TENS
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Cairo University
Location
Cairo, Egypt
Timeline & enrollment
Phase
N/A
Start date
Oct 01, 2023
End date
Oct 31, 2024
Enrollment
60 participants
Primary outcome

Doppler ultrasonography

Summary

Sixty elderly patients from both sexes with PAD, stage II fontaine will participate in this
 study. Their ages will be from 40-90 years old. They will be selected from kasr el ainy
 (faculty of medicine), Cairo University, Giza, Egypt. The patients will be randomly assigned
 into two equal groups:
 
 Group (A): 30 patients will receive transcutaneous electrical nerve stimulation (TENS) for 45
 minutes per session applied on calf muscle, combined with treadmill three days per week for
 twelve weeks in addition to the routine medical treatment.
 
 Group (B): 30 patients will receive treadmill training for 45 minutes per session, three days
 per week for twelve weeks in addition to the routine medical treatment

ICD-10 classifications
Peripheral vascular disease, unspecifiedOther peripheral vascular diseasesOther specified peripheral vascular diseasesPeripheral angiopathy in diseases classified elsewhereOther congenital malformations of peripheral vascular system
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06061211
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06061211 through Pure Global AI's free database. This phase not specified trial is sponsored by Cairo University and is currently Not yet recruiting. The study focuses on Peripheral Arterial Disease. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.